

Rabbit Anti-TIMP2 Recombinant [TIMP2/2488R]: RM0372, RM0372RTU7

Intended Use: For Research Use Only

Description: It recognizes a protein of 21kDa, identified as tissue inhibitor of metalloproteinases-2 (TIMP-2). It is closely related to TIMP-1 and shows the highest binding affinity to both the latent (pro) and active forms of 72kDa Type IV collagenase (also known as MMP-2 or gelatinase A). It also has affinity for the active form of 92kDa Type IV collagenase (also known as MMP-9 or gelatinase B). TIMP-2 inhibits the proteolytic invasiveness of tumor cells and normal placental trophoblast cells.


Specifications

Clone: TIMP2/2488R
 Source: Rabbit
 Isotype: IgG
 Reactivity: Human, mouse, rat, guinea, pig, rabbit, cow, zebrafish
 Immunogen: A synthetic peptide from the N-terminus of human TIMP2 protein (aa56-66) (DSGNDIYGNPI)
 Localization: Cytoplasm, membrane
 Formulation: Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN₃)
 Storage: Store at 2°- 8°C
 Applications: IHC
 Package:

Description	Catalog No.	Size
TIMP2 Recombinant [TIMP2/2488R] Concentrated	RM0372	1 ml
TIMP2 Recombinant [TIMP2/2488R] Prediluted	RM0372RTU7	7 ml

IHC Procedure

Positive Control Tissue: Normal placenta, breast, colon, endometrial, prostate or ovarian carcinoma, HeLa cells
 Concentrated Dilution: 50-200
 Pretreatment: Tris EDTA pH9.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual
 * Result should be confirmed by an established diagnostic procedure.



FFPE human placenta stained with anti-TIMP2 using DAB

References:

1. Mechanisms Underlying Increased TIMP2 and IGFBP7 Urinary Excretion in Experimental AKI. Johnson ACM et al. J Am Soc Nephrol. 2018.
2. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion. Yi X et al. Sci Rep. 2017.
3. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2: Prognostic biological markers in invasive prolactinomas. Gültekin GD, et al. J Clin Neurosci. Aug;22(8):1282-7, 2015.
4. Presence of matrix metalloproteinase-2 and tissue inhibitor matrix metalloproteinase-2 gene polymorphisms and immunohistochemical expressions in intracranial meningiomas. Coven İ, et al. J Neurosurg. Dec;121(6):1478-82, 2014.

Doc. 100-RM0372
Rev. A